Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer's disease

Neurobiology of Aging

Volumn 25, Issue 5, 2004, Pages 569-580

  Klein, W L ^a   Stine Jr , W B ^b   Teplow, D B ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Division of Geriatrics   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ADDLs; Alzheimer's disease; Amyloid; Amyloid protein; Neurotoxicity; Oligomers; Paranucleus; Protofibril

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN PROTEIN; NEUROTOXIN;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; CYTOPATHOLOGY; ENZYME ACTIVITY; ENZYME STRUCTURE; HUMAN; NERVE CELL LESION; NERVE CELL NECROSIS; NERVE INJURY; NEUROPATHOLOGY; NEUROTOXICITY; OLIGOMERIZATION; PATHOPHYSIOLOGY; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN MODIFICATION; PROTEIN PROCESSING; REVIEW;

EID: 2542455537     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2004.02.010     Document Type: Article

References (78)

1. Allison D.W., Chervin A.S., Gelfand V.I., Craig A.M. Postsynaptic scaffolds of excitatory and inhibitory synapses in hippocampal neurons: maintenance of core components independent of actin filaments and microtubules. J. Neurosci. 20:2000;4545-4554
2. Anfinsen C.B. Principles that govern the folding of protein chains. Science. 181:1973;223-230
3. Barnham K.J., Ciccotosto G.D., Tickler A.K., Ali F.E., Smith D.G., Williamson N.A., et al. Neurotoxic, redox-competent Alzheimer's β-amyloid is released from lipid membrane by methionine oxidation. J. Biol. Chem. 278:2003;42959-42965
4. Bigio E.H., Hynan L.S., Sontag E., Satumtira S., White C.L. Synapse loss is greater in presenile than senile onset Alzheimer disease: implications for the cognitive reserve hypothesis. Neuropathol. Appl. Neurobiol. 28:2002;218-227
5. Bitan G., Kirkitadze M.D., Lomakin A., Vollers S.S., Benedek G.B., Teplow D.B. Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways. Proc. Natl. Acad. Sci. U.S.A. 100:2003;330-335
6. Bitan G., Lomakin A., Teplow D.B. Amyloid β-protein oligomerization - prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J. Biol. Chem. 276:2001;35176-35184
7. 35 and amyloid β-protein oligomerization. J. Am. Chem. Soc. 125:2003;15359-15365
8. Bitan G., Vollers S.S., Teplow D.B. Elucidation of primary structure elements controlling early amyloid β-protein oligomerization. J. Biol. Chem. 278:2003;34882-34889
9. Chamberlain A.K., MacPhee C.E., Zurdo J., Morozova-Roche L.A., Hill H.A.O., Dobson C.M., et al. Ultrastructural organization of amyloid fibrils by atomic force microscopy. Biophys. J. 79:2000;3282-3293
10. Chang L., Bakhos L., Wang Z.Q., Venton D.L., Klein W.L. Femtomole immunodetection of synthetic and endogenous amyloid-β oligomers and its application to Alzheimer's disease drug candidate screening. J. Mol. Neurosci. 20:2003;305-313
11. 1-42 into globular neurotoxins. Biochemistry. 42:2003;12749-12760
12. Chui D.H., Tanahashi H., Ozawa K., Ikeda S., Checler F., Ueda O., et al. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat. Med. 5:1999;560-564
13. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U.S.A. 97:2000;571-576
14. Dahlgren K.N., Manelli A.M., Stine W.B., Baker L.K., Krafft G.A., LaDu M.J. Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J. Biol. Chem. 277:2002;32046-32053
15. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat. Neurosci. 5:2002;452-457
16. Fancy D.A., Denison C., Kim K., Xie Y.Q., Holdeman T., Amini F., et al. Scope, limitations and mechanistic aspects of the photo-induced cross-linking of proteins by water-soluble metal complexes. Chem. Biol. 7:2000;697-708
17. Gamkrelidze G, Shah C, Yun SH, Pasternak JF, Stine B, Manelli A. Differential effects of oligomeric amyloid-β on synaptic plasticity in human apoE targeted replacement mice. Soc Neurosci Abstr 2003;29:945.17.
18. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., et al. Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. U.S.A. 100:2003;10417-10422
19. Grabowski T.J., Cho H.S., Vonsattel J.P.G., Rebeck G.W., Greenberg S.M. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann. Neurol. 49:2001;697-705
20. Guzowski J.F. Insights into immediate-early gene function in hippocampal memory consolidation using antisense oligonucleotide and fluorescent imaging approaches. Hippocampus. 12:2002;86-104
21. Haass C., Steiner H. Protofibrils, the unifying toxic molecule of neurodegenerative disorders? Nat. Neurosci. 4:2001;859-860
22. Hardy J., Selkoe D.J. Medicine - the amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297:2002;353-356
23. Harper J.D., Wong S.S., Lieber C.M., Lansbury P.T. Observation of metastable Aβ amyloid protofibrils by atomic force microscopy. Chem. Biol. 4:1997;119-125
24. Hartley D.M., Walsh D.M., Ye C.P.P., Diehl T., Vasquez S., Vassilev P.M., et al. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19:1999;8876-8884
25. Hoshi M., Sato M., Matsumoto S., Noguchi A., Yasutake K., Yoshida N., et al. Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β Proc. Natl. Acad. Sci. U.S.A. 100:2003;6370-6375
26. Howlett D.R., Jennings K.H., Lee D.C., Clark M.S., Brown F., Wetzel R., et al. Aggregation state and neurotoxic properties of Alzheimer β-amyloid peptide. Neurodegeneration. 4:1995;23-32
27. Jarrett J.T., Berger E.P., Lansbury P.T. Jr. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 32:1993;4693-4697
28. Johansson A.-S., Päiviö A., Lannfelt L., Westlind-Danielsson A. Oxidation induced changes of β-amyloid peptide fibrillization rate - possible implications for Alzheimer's disease. Neurobiol. Aging. 23:2002;S187
29. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 300:2003;486-489
30. Kelly M.P., Deadwyler S.A. Experience-dependent regulation of the immediate-early gene Arc differs across brain regions. J. Neurosci. 23:2003;6443-6451
31. Kirkitadze M.D., Condron M.M., Teplow D.B. Identification and characterization of key kinetic intermediates in amyloid β-protein fibrillogenesis. J. Mol. Biol. 312:2001;1103-1119
32. Klein WL. Aβ toxicity in Alzheimer's disease. In: Chesselet MF, editor. Molecular mechanisms of neurodegenerative diseases. Totowa, NJ: Humana Press; 2000. p. 1-49.
33. Klein W.L., Krafft G.A., Finch C.E. Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 24:2001;219-224
34. Kotilinek L.A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B.T., et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22:2002;6331-6335
35. Kraepelin E. Psychiatrie: ein lehrbuch für studierende und ärzte, vol. 2, 8th ed. Leipzig: J. Barth; 1910.
36. Kuo Y.M., Emmerling M.R., Vigo-Pelfrey C., Kasunic T.C., Kirkpatrick J.B., Murdoch G.H., et al. Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 271:1996;4077-4081
37. Lacor PN, Viola KL, Fernandez S, Velasco PT, Bigio EH, Klein WL. Targeting of synapses and memory-linked IEG protein Arc by ADDLs. Soc Neurosci Abstr 2003;29:945.14.
38. 1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 95:1998;6448-6453
39. Lambert M.P., Viola K.L., Chromy B.A., Chang L., Morgan T.E., Yu J.X., et al. Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies. J. Neurochem. 79:2001;595-605
40. Lomakin A., Benedek G.B., Teplow D.B. Monitoring protein assembly using quasielastic light scattering spectroscopy. Methods Enzymol. 309:1999;429-459
41. Lue L.F., Kuo Y.M., Roher A.E., Brachova L., Shen Y., Sue L., et al. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155:1999;853-862
42. Manelli A, Guo L, White JA, VanEldik LJ, LaDu MJ. Glial activation by oligomeric versus fibrillar Aβ1-42. Soc Neurosci Abstr 2002;28:193-9.
43. Manelli AM, Stine Jr WB, Van Eldik LJ, LaDu MJ. ApoE and Aβ1-42 interactions: effects of isoform and conformation on structure and function. J Mol Neurosci 2004, in press.
44. Manelli AM, Sullivan PM, LaDu MJ. Aβ1-42 induced neurotoxicity in cells co-cultured with glia from apoE targeted replacement mice. Soc Neurosci Abstr 2003;29:407-18.
45. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46:1999;860-866
46. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:2000;982-985
47. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., et al. High-level neuronal expression of Aβ(1-42) in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20:2000;4050-4058
48. Näslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., et al. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA. 283:2000;1571-1577
49. Nilsberth C., Westlind-Danielsson A., Eckman C.B., Condron M.M., Axelman K., Forsell C., et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation. Nat. Neurosci. 4:2001;887-893
50. 1-42) and forms slowly sedimenting Aβ complexes that cause oxidative stress. Exp. Neurol. 136:1995;22-31
51. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron. 39:2003;409-421
52. Palmblad M., Westlind-Danielsson A., Bergquist J. Oxidation of methionine 35 attenuates formation of amyloid β-peptide 1-40 oligomers. J. Biol. Chem. 277:2002;19506-19510
53. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.G., Cotman C.W. Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13:1993;1676-1687
54. Rebeck G.W., Kindy M., LaDu M.J. Apolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3. J. Alzheimers Dis. 4:2002;145-154
55. Rial Verde EM, Worley P, Malinow R, Cline HT. The immediate-early gene Arc regulates AMPA-receptor trafficking. Soc Neurosci Abstr 2003;29:55-7.
56. Rochet J.C., Lansbury P.T. Jr. Amyloid fibrillogenesis: themes and variations. Curr. Opin. Struct. Biol. 10:2000;60-68
57. Roher A.E., Chaney M.O., Kuo Y.M., Webster S.D., Stine W.B., Haverkamp L.J., et al. Morphology and toxicity of Aβ(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J. Biol. Chem. 271:1996;20631-20635
58. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., et al. Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177
59. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science. 298:2002;789-791
60. Serio T.R., Cashikar A.G., Kowal A.S., Sawicki G.J., Moslehi J.J., Serpell L., et al. Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science. 289:2000;1317-1321
61. Shah C, Gamkrelidze G, Yun SH, Pasternak J, Sotak M, Ye G. Synaptic plasticity in apoE replacement mice. Soc Neurosci Abstr 2003;29:730.1.
62. Small D.H. The Sixth International Conference on Alzheimer's disease, Amsterdam, The Netherlands, July 1998. The amyloid cascade hypothesis debate: emerging consensus on the role of Aβ and amyloid in Alzheimer's disease. Amyloid. 5:1998;301-304
63. Snyder S.W., Ladror U.S., Wade W.S., Wang G.T., Barrett L.W., Matayoshi E.D., et al. Amyloid-β aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys. J. 67:1994;1216-1228
64. Soto C., Castaño E.M., Kumar R.A., Beavis R.C., Frangione B. Fibrillogenesis of synthetic amyloid-β peptides is dependent on their initial secondary structure. Neurosci. Lett. 200:1995;105-108
65. Stine W.B., Dahlgren K.N., Krafft G.A., LaDu M.J. In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis. J. Biol. Chem. 278:2003;11612-11622
66. Stine W.B. Jr., Snyder S.W., Ladror U.S., Wade W.S., Miller M.F., Perun T.J., et al. The nanometer-scale structure of amyloid-β visualized by atomic force microscopy. J. Protein Chem. 15:1996;193-203
67. Taylor B.M., Sarver R.W., Fici G., Poorman R.A., Lutzke B.S., Molinari A., et al. Spontaneous aggregation and cytotoxicity of the β-amyloid Aβ(1-40): a kinetic model. J. Protein Chem. 22:2003;31-40
68. Teplow D.B. Structural and kinetic features of amyloid β-protein fibrillogenesis. Amyloid: Int. J. Exp. Clin. Invest. 5:1998;121-142
69. Teplow DB, Lomakin A, Benedek GB, Kirschner DA, Walsh DM. Effects of β-protein mutations on amyloid fibril nucleation and elongation. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM, editors. Alzheimer's disease: biology, diagnosis and therapeutics. Chichester, UK: John Wiley & Sons Ltd.; 1997. p. 311-9.
70. Varadarajan S., Kanski J., Aksenova M., Lauderback C., Butterfield D.A. Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's Aβ(1-42) and Aβ(25-35). J. Am. Chem. Soc. 123:2001;5625-5631
71. Varadarajan S., Yatin S., Aksenova M., Butterfield D.A. Alzheimer's amyloid β-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 130:2000;184-208
72. Wakutani Y, Watanabe K, Adachi Y, Wada-Isoe K, Urakami K, Ninomiya H. Novel amyloid precursor protein gene missense mutation (D678N) in familial Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004, in press.
73. Walsh D.M., Hartley D.M., Kusumoto Y., Fezoui Y., Condron M.M., Lomakin A., et al. Amyloid β-protein fibrillogenesis - structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274:1999;25945-25952
74. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 416:2002;535-539
75. Walsh D.M., Lomakin A., Benedek G.B., Condron M.M., Teplow D.B. Amyloid β-protein fibrillogenesis - detection of a protofibrillar intermediate. J. Biol. Chem. 272:1997;22364-22372
76. Wang H.W., Pasternak J.F., Kuo H., Ristic H., Lambert M.P., Chromy B., et al. Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924:2002;133-140
77. Westerman M.A., Chang L., Frautschy S., Kotilinek L., Cole G., Klein W., et al. Ibuprofen reverses memory loss in transgenic mice modeling Alzheimer's disease. Soc. Neurosci Abstr. 28:2002;690.4
78. Westlind-Danielsson A., Arnerup G. Spontaneous in vitro formation of supramolecular β-amyloid structures, "βamyballs", by β-amyloid 1-40 peptide. Biochemistry. 40:2001;14736-14743